Results 191 to 200 of about 177,264 (261)

Is there a relationship between the use of phosphodiesterase type 5 inhibitors and testosterone levels in men?

Tripdatabase
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phosphodiesterase type 5 inhibitors and kidney disease

International Urology and Nephrology, 2015
Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin-angiotensin system blockers.
Baris, Afsar, Alberto, Ortiz, Adrian, Covic, Abduzhappar, Gaipov, Tarik, Esen, David, Goldsmith, Mehmet, Kanbay   +6 more
openaire   +3 more sources

Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?

Journal of Sexual Medicine, 2020
BACKGROUND Priapism is an adverse drug reaction (ADR) associated with phosphodiesterase type 5 inhibitors (PDE5is) in the treatment of erectile dysfunction.
Michael E. Rezaee, M. Gross
semanticscholar   +1 more source

Phosphodiesterase Type 5 Inhibitors: Unmet Needs

Current Pharmaceutical Design, 2009
Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety ...
K, Hatzimouratidis, D G, Hatzichristou
openaire   +2 more sources

Phosphodiesterase Type 5 Inhibitors: The Day After

European Urology, 2007
Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is), addressing critical issues in their current and future use, assessing unanswered questions, and identifying research needs.A MEDLINE search was conducted on PDE5-Is, with emphasis on clinical trials and experience, for interpretation and analysis of their present and future role ...
Konstantinos, Hatzimouratidis, Dimitrios, Hatzichristou   +1 more
openaire   +2 more sources

Phosphodiesterase type 5 inhibitors for erectile dysfunction

BJU International, 2005
This is our first presentation of Great Drug Classes, and we start with a description of phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth review of this class of drugs, offering the reader a description of how they work, in which conditions they may be particularly beneficial, and a ...
Culley C, Carson, Tom F, Lue
openaire   +2 more sources

Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension

New England Journal of Medicine, 2009
A 46-year-old-woman presents with exertional dyspnea and syncope and receives a diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine monophosphate in the ...
Stephen L, Archer, Evangelos D, Michelakis   +1 more
openaire   +4 more sources

Phosphodiesterase Type 5 (PDE5) Inhibitors

2003
Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning, Ulrich, Niewöhner, Erwin, Bischoff   +2 more
openaire   +2 more sources

Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction?

European Urology, 2006
To systematically analyze and review the available evidence about the potential role of chronic administration of phosphodiesterase type 5 (PDE-5) inhibitors for the cure of erectile dysfunction (ED) based on clinical and basic science data.Analysis of published full-length papers that were identified with Medline and Cancerlit from January 1993 to ...
MONTORSI , FRANCESCO, BRIGANTI , ALBERTO, SALONIA , ANDREA, Rigatti P, Burnett AL   +4 more
openaire   +3 more sources

Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.

Journal of Medicinal Chemistry, 2019
Phosphodiesterase type 5 (PDE5) inhibitors are first-line therapy for pulmonary arterial hypertension (PAH) and erectile dysfunction. As a continuing work to improve the terminal half-lives and oral bioavailabilities of our previously reported 4(3 H ...
Zhen Wang, Xiangrui Jiang, Xianglei Zhang, Guanghui Tian, Rulei Yang, Jianzhong Wu, Xiaoli Zou, Zheng Liu, Xiaojun Yang, Chunhui Wu, Jing Shi, Jianfeng Li, J. Suo, Yu Wang, Rongxia Zhang, Zhijian Xu, Xu-Bin Gong, Yang He, Weiliang Zhu, H. Aisa, Hualiang Jiang, Yechun Xu, Jingshan Shen   +22 more
semanticscholar   +1 more source